chevron_leftBack
As of 13 June 2026, Damora Therapeutics, Inc. has a market cap of $1.44B USD, ranking #8686 globally and #1921 in the United States.
It ranks #729 in the Healthcare sector, and #143 in the Biotechnology industry.
Key Stats
Market Cap
$1.44BUSD
Enterprise Value
$1.13BUSD
EBITDA (TTM)
-$36.54MUSD
Net Income (TTM)
-$209.84MUSD
PB Ratio
5.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Jennifer Jarrett
open_in_new
Employees
7
Founded
2011
IPO
29 Oct 2020
Website
damoratx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -7.6% | -6.2% | -2.2% | 234% | 793% |
News
Loading...
GLTO Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GLTO
Galecto Inc Ordinary Shares
ISIN: US36322Q2066
Shares Out.:
Shares Outstanding:
60.24M1
Shares Float:
55.645M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
23.92 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
13K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
11K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
2K%
|
-
|
|
NYSE: IQV
|
$26.3B
2K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
2K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
1K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
3K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
3K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
3K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
3K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
2K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
2K%
|
-
|
chevron_leftBack